基本信息:
- 专利标题： METHOD FOR EVALUATING CANCER
- 专利标题（中）：VERFAHREN ZUR TUMORBEURTEILUNG
- 申请号：EP10767100.0 申请日：2010-04-21
- 公开(公告)号：EP2423323A1 公开(公告)日：2012-02-29
- 发明人： KURODA, Masahiko , SAITO, Akira , SANO, Maki
- 申请人： NEC Corporation , TOKYO MEDICAL UNIVERSITY
- 申请人地址： 7-1, Shiba 5-chome Minato-ku Tokyo 108-8001 JP
- 专利权人： NEC Corporation,TOKYO MEDICAL UNIVERSITY
- 当前专利权人： NEC Corporation,TOKYO MEDICAL UNIVERSITY
- 当前专利权人地址： 7-1, Shiba 5-chome Minato-ku Tokyo 108-8001 JP
- 代理机构： Glawe, Delfs, Moll
- 优先权： JP2009103332 20090421
- 国际公布： WO2010123043 20101028
- 主分类号： C12Q1/68
- IPC分类号： C12Q1/68 ; C12N15/09 ; C12Q1/02
摘要：
Provided is a cancer evaluation method using a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject. At least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as the novel cancer marker in cancer evaluation. The cancer marker in a sample of a cell or a tissue is detected, and the possibility of a cancer in the sample is evaluated based on the expression level of the cancer marker. According to this evaluation method, by detecting the miRNA as the cancer marker, it becomes possible to evaluate the possibility of a cancer in the sample with excellent reliability. As a method for detecting the cancer marker, it is preferable to perform an in situ hybridization method using a labeled probe with respect to the sample that has been immobilized, for example.
摘要（中）：
提供了一种使用新型癌症标记物评估受试者的癌症的发病，临床前期，临床阶段或预后的癌症评价方法。 使用至少一种选自hsa-miR-92和hsa-miR-494的miRNA作为癌症评估中的新型癌症标志物。 检测细胞或组织样品中的癌症标志物，并根据癌症标志物的表达水平评估样品中癌症的可能性。 根据该评价方法，通过检测miRNA作为癌症标记物，可以以极好的可靠性来评价样品中癌症的可能性。 作为检测癌症标记物的方法，优选使用例如相对于固定化样品的标记探针进行原位杂交法。